Concepedia

Author

Nataša Cmiljanović

PIQUR Therapeutics (Switzerland)

Also Known As

Cmiljanović, Nataša, N. Cmiljanovic, Natasa Cmiljanovic, Nataša Cmiljanović

14

Publications

339

Citations

5

H-Index

16

Concepts

All Affiliations

PIQUR Therapeutics (Switzerland)University Hospital of BaselUniversity of BaselMRC Laboratory of Molecular BiologyUniversity College London
NC

About

Nataša Cmiljanović is an author at PIQUR Therapeutics (Switzerland) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

194

2

Pharmacology

2

2

194

3

Immunology

1

1

132

4

Cancer Therapeutics

1

1

62

5

Drug Development

1

1

132

Nataša Cmiljanović

×

4

Publications

318

Citations

4

H-Index

YearCitations

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović,

Journal of Medicinal Chemistry

2017

132

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, A.E. Prota, Florent Beaufils,

Nature Communications

2017

113

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas,

European Journal of Cancer

2018

62

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Filip Jankú, Grace M. Choong, Mateusz Opyrchal,

Cancers

2024

11

Page 1